Cargando…

A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector

BACKGROUND: The rational use of medicine is fundamental to ensure effective and safe patient medicine treatment, and hence, should be monitored. Undisputable evidence exists for the teratogenic risk factors associated with sodium valproate. Consequently, the Western Cape Department of Health introdu...

Descripción completa

Detalles Bibliográficos
Autores principales: Keuler, Nicole, Johnson, Yasmina, Coetzee, Renier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257847/
https://www.ncbi.nlm.nih.gov/pubmed/35695446
http://dx.doi.org/10.4102/safp.v64i1.5402
_version_ 1784741416034893824
author Keuler, Nicole
Johnson, Yasmina
Coetzee, Renier
author_facet Keuler, Nicole
Johnson, Yasmina
Coetzee, Renier
author_sort Keuler, Nicole
collection PubMed
description BACKGROUND: The rational use of medicine is fundamental to ensure effective and safe patient medicine treatment, and hence, should be monitored. Undisputable evidence exists for the teratogenic risk factors associated with sodium valproate. Consequently, the Western Cape Department of Health introduced a policy (2019) recommending alternatives for valproate in women of childbearing age, including lamotrigine or levetiracetam as alternatives for patients on antiretrovirals. This study aimed to describe the change in the consumption of valproate, lamotrigine and levetiracetam after a policy implementation in public sector health facilities of the Western Cape, South Africa. METHODS: This observational study followed a quasi-experimental design. Consumption data from the Cape Medical Depot over the period 01 April 2018 to 31 March 2020 were analysed retrospectively. Consumption was presented as a defined daily dose (DDD) per 1000 population per quarter for sodium valproate, levetiracetam and lamotrigine for the Western Cape province, urban and rural areas. Consumption 12 months before was compared with consumption 12 months after policy implementation. RESULTS: Post-policy implementation, valproate consumption remained unchanged provincially (3.3%; p = 0.255), in urban (7.8%; p = 0.255) and rural (1.5%; p = 0.701) areas. Lamotrigine consumption increased significantly provincially (30.7%; p = 0.020) and in urban areas (54.5%; p = 0.002); however, rural (26.1%; p = 0.108) areas did not show significant change. Provincially, valproate consumption remained substantially higher (209 DDDs/1000 population per quarter) compared with lamotrigine consumption (32.22 DDDs/1000 population per quarter). CONCLUSION: In the Western Cape public sector, the consumption of sodium valproate remained unchanged 12 months after policy implementation. Although there were significant increases in lamotrigine and levetiracetam consumption, the consumption was considerably less compared with sodium valproate consumption.
format Online
Article
Text
id pubmed-9257847
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AOSIS
record_format MEDLINE/PubMed
spelling pubmed-92578472022-07-07 A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector Keuler, Nicole Johnson, Yasmina Coetzee, Renier S Afr Fam Pract (2004) Original Research BACKGROUND: The rational use of medicine is fundamental to ensure effective and safe patient medicine treatment, and hence, should be monitored. Undisputable evidence exists for the teratogenic risk factors associated with sodium valproate. Consequently, the Western Cape Department of Health introduced a policy (2019) recommending alternatives for valproate in women of childbearing age, including lamotrigine or levetiracetam as alternatives for patients on antiretrovirals. This study aimed to describe the change in the consumption of valproate, lamotrigine and levetiracetam after a policy implementation in public sector health facilities of the Western Cape, South Africa. METHODS: This observational study followed a quasi-experimental design. Consumption data from the Cape Medical Depot over the period 01 April 2018 to 31 March 2020 were analysed retrospectively. Consumption was presented as a defined daily dose (DDD) per 1000 population per quarter for sodium valproate, levetiracetam and lamotrigine for the Western Cape province, urban and rural areas. Consumption 12 months before was compared with consumption 12 months after policy implementation. RESULTS: Post-policy implementation, valproate consumption remained unchanged provincially (3.3%; p = 0.255), in urban (7.8%; p = 0.255) and rural (1.5%; p = 0.701) areas. Lamotrigine consumption increased significantly provincially (30.7%; p = 0.020) and in urban areas (54.5%; p = 0.002); however, rural (26.1%; p = 0.108) areas did not show significant change. Provincially, valproate consumption remained substantially higher (209 DDDs/1000 population per quarter) compared with lamotrigine consumption (32.22 DDDs/1000 population per quarter). CONCLUSION: In the Western Cape public sector, the consumption of sodium valproate remained unchanged 12 months after policy implementation. Although there were significant increases in lamotrigine and levetiracetam consumption, the consumption was considerably less compared with sodium valproate consumption. AOSIS 2022-06-02 /pmc/articles/PMC9257847/ /pubmed/35695446 http://dx.doi.org/10.4102/safp.v64i1.5402 Text en © 2022. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
spellingShingle Original Research
Keuler, Nicole
Johnson, Yasmina
Coetzee, Renier
A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
title A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
title_full A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
title_fullStr A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
title_full_unstemmed A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
title_short A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
title_sort description of sodium valproate, lamotrigine and levetiracetam consumption in the western cape public sector
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257847/
https://www.ncbi.nlm.nih.gov/pubmed/35695446
http://dx.doi.org/10.4102/safp.v64i1.5402
work_keys_str_mv AT keulernicole adescriptionofsodiumvalproatelamotrigineandlevetiracetamconsumptioninthewesterncapepublicsector
AT johnsonyasmina adescriptionofsodiumvalproatelamotrigineandlevetiracetamconsumptioninthewesterncapepublicsector
AT coetzeerenier adescriptionofsodiumvalproatelamotrigineandlevetiracetamconsumptioninthewesterncapepublicsector
AT keulernicole descriptionofsodiumvalproatelamotrigineandlevetiracetamconsumptioninthewesterncapepublicsector
AT johnsonyasmina descriptionofsodiumvalproatelamotrigineandlevetiracetamconsumptioninthewesterncapepublicsector
AT coetzeerenier descriptionofsodiumvalproatelamotrigineandlevetiracetamconsumptioninthewesterncapepublicsector